Our partner is a pioneering biotech company advancing novel treatments for obesity rooted in breakthrough science from the University of Pennsylvania.

In this pivotal executive role, the newly appointed CEO will steer corporate strategy, scientific direction, and long-term growth while collaborating closely with the Board and scientific founders. Their leadership will drive preclinical progress, investor engagement, and regulatory alignment to bring safer, more effective therapies to patients affected by cardiometabolic conditions. As part of a visionary leadership team, they will help shape the future of obesity treatment by building a high-performing organization committed to both innovation and impact.